BXP (BXP) has set up a broad capital-raising toolkit, filing new shelf registrations across multiple securities and a US$1b at-the-market common stock program, while also withdrawing a planned US$600m offering.
See our latest analysis for BXP.
The new capital program lands after a weak patch for the stock, with a 30 day share price return of 20.23% decline and a year to date share price return of 22.25% decline. At the same time, the 3 year total shareholder return of 17.14% suggests longer term investors have still seen gains. Recent volatility may reflect shifting views on BXP’s funding mix and risk rather than a simple one way trend.
If this capital raise has you thinking about where else capital is flowing, it could be a good moment to look at 23 power grid technology and infrastructure stocks as another way to find potential grid focused infrastructure ideas.
With BXP trading at US$52.73 and sitting at a 40.98% intrinsic discount alongside a 38.73% discount to analyst targets, the key question is whether this gap signals a genuine opportunity or if markets already see weaker growth ahead.
Most Popular Narrative: 29.4% Undervalued
The most followed narrative pegs BXP's fair value at $74.65 compared to the last close of $52.73, framing today's price as a discount that depends on how its office and life science portfolio performs over the next decade.
The company's investment in highly amenitized, sustainable, and green-certified developments (e.g., 343 Madison), supported by strong pre-leasing to blue-chip, investment-grade tenants, is described as benefiting from tenant ESG priorities, enabling BXP to achieve outsized rent growth and robust development yields, thereby enhancing long-term revenue and net margin profiles.
Curious what kind of revenue change, margin shift, and future earnings multiple would need to align for that $74.65 number to be supported? The narrative references measured top line growth, a steady build in profitability, and a premium earnings multiple that assumes investors will keep paying up for premier offices in key markets. Want to see exactly how those moving parts are integrated into that fair value estimate and where the biggest swing factor sits? Read the full story behind the model.
Result: Fair Value of $74.65 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still the risk that softer life science and tech leasing, combined with higher capital needs at 343 Madison, could strain occupancy and cash generation.
Find out about the key risks to this BXP narrative.
Another Way To Look At BXP's Price
That 29.4% undervaluation story leans on a fair value estimate of $74.65. If you step back and just look at earnings, BXP trades on a P/E of 30.2x versus 16x for the global Office REITs group and a fair ratio of 35.7x, which suggests less of a clear-cut bargain. So is this a discount, or simply different expectations being priced in?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of potential upside and concern feels finely balanced, do not wait around. Check the full picture with 4 key rewards and 4 important warning signs.
Looking for more investment ideas?
If this news has sharpened your focus, do not stop with a single stock. Cast the net wider now so you are not looking back later wishing you had.
- Zero in on quality at a discount by scanning our 47 high quality undervalued stocks that pair solid fundamentals with prices below their assessed worth.
- Strengthen your income stream by checking out 15 dividend fortresses, featuring companies with higher yields and a focus on consistent payouts.
- Prioritize resilience by reviewing 68 resilient stocks with low risk scores, highlighting businesses with lower risk scores and steadier profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com